<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02270268</url>
  </required_header>
  <id_info>
    <org_study_id>2011NLY073</org_study_id>
    <nct_id>NCT02270268</nct_id>
  </id_info>
  <brief_title>Effects of Pectin Supplementation in Diarrhea-predominant Irritable Bowel Syndrome</brief_title>
  <official_title>Therapeutic Effects of Pectin Supplementation in Patients With Diarrhea-predominant Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing PLA General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of pectin, a kind of soluble dietary
      fiber, on clinical symptoms, gut microbiota and the immune status in patients with
      diarrhea-predominant irritable bowel syndrome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were randomized to receive either pectin or placebo. Treatment consisted of 6 weeks
      supplementation with pectin (fiber group) or placebo (maltodextrin). We evaluated the
      clinical symptoms, gut microbiota and the immune markers in two groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy: change of stool frequency, faecal form and clinical symptoms score</measure>
    <time_frame>six weeks after inclusion</time_frame>
    <description>change from baseline in stool frequency, faecal form (Bristol stool scale) and clinical symptoms score (7-point Likert scale) at six weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy: gut microbiota</measure>
    <time_frame>six weeks after inclusion</time_frame>
    <description>real-time PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy: cytokine ratios</measure>
    <time_frame>six weeks after inclusion</time_frame>
    <description>Cytokine production</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>pectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a kind of soluble dietary fiber</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pectin</intervention_name>
    <description>Pectin （Andeli Ltd. Yantai, China）, 24g/d for six weeks</description>
    <arm_group_label>pectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>maltodextrin</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients(age≧18y)

          -  Admitted for diarrhea-predominant irritable bowel syndrome

        Exclusion Criteria:

          -  Mental disorders

          -  Cancer

          -  Inflammatory bowel disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tao Gao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing PLA General Hospital</affiliation>
  </overall_official>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2014</study_first_submitted>
  <study_first_submitted_qc>October 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>March 23, 2016</last_update_submitted>
  <last_update_submitted_qc>March 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Gao Tao</investigator_full_name>
    <investigator_title>Nanjing PLA General Hospital</investigator_title>
  </responsible_party>
  <keyword>Irritable bowel syndrome</keyword>
  <keyword>Gut microbiota</keyword>
  <keyword>Soluble dietary fiber</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

